AnteoTech Cuts Losses 36% as Silicon Anode Tech Hits 1,020 Cycles at 80% Retention

Anteotech Half Year Results 2026: leaner cost base, deeper pipelines, clear path to growth

AnteoTech (ASX: ADO) has reported its Anteotech Half Year Results 2026 for the period ended 31 December 2025, marking a structural inflection point for the surface-modification specialist. The half-year update reveals a 36% reduction in pre-tax loss, a 24% cut in total expenses, and a reset cost base now positioned to amplify the impact of any new revenue wins across Advanced Battery Technologies (ABT) and Life Sciences (LS).

Sales revenue of $97k came in below the prior corresponding period’s $660k, driven entirely by the timing of a Serum Institute of India (SII) contract payment received five days after period-end on 5 January 2026. Adjusting for this timing, underlying sales to other customers actually increased 6%, while the company’s pre-tax loss narrowed to -$1.4m from -$2.2m.

Cash at bank on 31 January 2026 stood at $1.56m, with no debt and including $402,950 from an in-progress capital raise. Management subsequently closed a $3.5m (net) capital raise on 4 February 2026, providing runway to execute on an expanding commercialisation pipeline across both divisions.

The half-year update positions the business as transitioning from heavy development spend to a leaner, more commercial-focused platform, with expanding sales pipelines and technical milestones serving as key leading indicators for future financial performance.

Top headlines from the period:

• Cost base structurally reset, with 31% staff cost reduction and -$1.27m total expense savings year-on-year.
• Pre-tax loss narrowed 36% to -$1.4m despite revenue timing impact.
• Fresh $3.5m capital raise completed post-period, strengthening balance sheet.
• Ultranode X achieved 1,020 cycles at 80% capacity retention, demonstrating market-leading silicon anode performance.
• SII five-year take-or-pay contract execution continues, with one more payment expected in FY26.

Financial reset and revenue base: what changed in H1 FY2026

The Anteotech Half Year Results 2026 provide a detailed view of the financial recalibration underway at (ASX: ADO). Revenue declined, expenses fell sharply, and the balance sheet strengthened. The numbers tell the story of a business moving deliberately from development-heavy spending to a commercial-focused posture, with cost reductions creating meaningful operating leverage if revenue scales.

Revenue and the Serum Institute timing effect

Reported sales revenue fell 85% to $97k from $660k in the prior corresponding period, driven almost entirely by the timing of the Serum Institute of India (SII) take-or-pay contract payment. SII remitted US$185k (~A$275,750) on 5 January 2026, just five days after period-end. Had this payment been included, H1 FY2026 sales would have totalled $372,750, materially reducing the headline revenue variance.

Excluding SII from both periods, sales to other customers increased 6%, indicating modest underlying growth in the broader customer base. Management noted that one additional SII payment is expected during FY2026, which would take total SII orders for the year to approximately A$550k compared to three orders in the prior year. The SII agreement, signed in July 2024, commits the Indian vaccine manufacturer to a US$1.8m take-or-pay supply arrangement over 2024 to 2029, providing a contracted revenue anchor that validates the AnteoBind platform and supports multi-year recurring income.

Cost reductions and margin leverage

Total expenses fell 24% to $4.11m from $5.38m, reflecting a structural reset across staff, contractors, directors, and operating overhead. Research expenses declined 31% to $1.36m, administration and occupancy costs dropped 14% to $1.58m, and share-based payment expenses fell 57% to $282k.

Specific savings include:

• 31% reduction in full-time equivalent (FTE) staff costs.
• 35% reduction in contract employee costs.
• Directors’ costs reduced by approximately $114k per annum.
• Interstate travel and accommodation costs reduced to nil.

The tighter cost base reduces the quantum of near-term dilutive capital required to sustain operations and increases the leverage to any future revenue growth. Every incremental dollar of sales now flows through a materially lower fixed-cost structure, improving the path to profitability and reducing the time to breakeven if commercialisation progresses as anticipated.

Cash, capital raise and runway

Cash at bank on 31 January 2026 stood at $1.56m, including $402,950 from a capital raise in progress. The company carries no debt. Post-period, management completed a $3.5m (net) capital raise on 4 February 2026, strengthening the balance sheet and providing runway to pursue key milestones and partnership conversions through the second half of FY26.

Management highlighted that expected 2026 R&D rebate receipts and contracted sales from SII provide additional funding sources. The absence of debt gives the company flexibility in navigating early commercial stages and allows management to focus on converting the expanding sales pipeline into revenue without immediate pressure to raise additional capital.

Technology and markets: how ABT and Life Sciences drive the ADO investment story

AnteoTech operates as a surface-modification and cross-linking specialist, commercialising two platforms: Advanced Battery Technologies (ABT) and Life Sciences (LS). The company’s core technology uses proprietary chemistry to “cross-link” molecules at a surface level, creating stronger, more durable and more functional materials. This platform approach supports multiple product lines across large and growing markets, increasing optionality and scalability.

Educational explainer: what AnteoTech actually does

At a high level, AnteoTech’s technology modifies the surface properties of materials to improve performance. Cross-linking refers to the formation of chemical bonds between molecules, which strengthens the structure and enhances functionality. In battery components, cross-linking improves the mechanical stability and electrochemical performance of silicon anodes and ceramic-coated separators. In diagnostic particles and plates, cross-linking increases the binding efficiency of antibodies and antigens, improving test sensitivity and reliability.

The main product families are:

• Advanced Battery Technologies (ABT):

• Cross-linkers for silicon anodes (Anteo X, Ultranode 70, Ultranode X, Ultranode 95) and ceramic-coated separators (Anteo S).

• Ultranode high-silicon anode technology targets electric vehicles, micro-mobility, drones and defence applications.

• Life Sciences (LS):

• Binding chemistries (AnteoBind Multiplex Activation kit, AnteoBind Biosensor, AnteoBind NXT) to improve the sensitivity, reliability and cost-effectiveness of immunodiagnostic tests including chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA) and lateral flow formats.

• Customers include the Serum Institute of India and emerging diagnostic platform partners.

The same underlying chemistry supports multiple product lines, positioning AnteoTech as a platform technology company with applications across structurally growing markets in battery materials and diagnostics.

ABT: silicon anode leadership and partnership momentum

The Advanced Battery Technologies division made substantial operational progress during the half-year, moving from laboratory development to real customer integration and joint development agreement (JDA) negotiations.

Ultranode X achieved 1,020 cycles at 80% capacity retention on a 70% silicon anode, achieving market-leading capabilities. The milestone validates the core cross-linking chemistry and supports ongoing discussions with potential strategic partners for licensing or JDA arrangements.

Ultranode 95, targeting drone and defence markets, is under negotiation for two non-exclusive JDAs with battery manufacturers that supply or intend to supply drones to the US defence sector and other end users. Internal modelling suggests Ultranode 95 can deliver a +40% increase in energy density (Wh/kg “active stack”) compared to graphite-based anodes, a critical advantage for applications requiring longer flight times and reduced weight.

The SiMRAX joint product JDA with Black Diamond Structures (BDS) combines AnteoTech’s Anteo X cross-linker with BDS’s single-walled carbon nanotube (SWCNT) dispersion technology. The collaboration aims to improve the mechanical stability, battery life and electrochemical performance of high-silicon anodes (greater than 15wt.% silicon). Early market test samples were dispatched in early March 2026 to six target companies.

Collaboration with Wyon (Switzerland), a medical device battery manufacturer, progressed with a 10x scale-up of anode production achieved and integration into Wyon battery cells in progress. The partnership demonstrates the scalability of the Ultranode 70 technology and its applicability in regulated, high-reliability markets.

Anteo S, a new separator cross-linker product, launched during the period. The product is designed to reinforce ceramic coatings on battery separators, reducing the potential for thermal runaway and fires. Strong sample demand emerged in South Korea via distributor Kangshin, supported by Austrade connections to large corporates. The global separator market was approximately US$14bn in 2024 and is projected to reach US$25bn by 2030, representing a compound annual growth rate (CAGR) of approximately 28%.

US market entry initiatives and regulatory approvals are being pursued, with distributor or agent options in progress and large-scale product import approvals being secured.

Why High-Silicon Anodes Matter

Silicon can store close to 10 times more lithium ions by weight and 3 times more by volume compared to graphite. Ultranode technology enables silicon to be used at its full potential, with Ultranode 95 delivering an estimated 40% increase in active stack energy density compared to graphite anodes in internal modelling. This translates to longer battery life and reduced system weight, critical advantages in electric vehicles, drones and defence applications.

ABT near-term commercial vectors:

1. Ultranode licensing and JDA negotiations.
2. SiMRAX product commercialisation with Black Diamond Structures.
3. Anteo S separator adoption via distributors in South Korea and other markets.
4. Regional expansion (Korea, US, Europe) supported by Austrade and Trade & Investment Queensland (TIQ).

Multiple ABT pathways (Ultranode, Anteo X, Anteo S, SiMRAX) diversify the route to revenue and reduce reliance on any single product or partnership. The division is now clearly in the commercialisation phase, with customer integration and JDA negotiations replacing pure research and development activity.

Life Sciences: building on Serum Institute and expanding the diagnostic footprint

The Life Sciences division continued execution of the Serum Institute of India (SII) contract during the half-year, with a recent order payment of US$185k (~A$275,750) received on 5 January 2026. The SII contract, valued at US$1.8m over 2024 to 2029, operates on a take-or-pay basis, providing revenue certainty and validating the AnteoBind platform in a high-volume, high-quality diagnostic application. SII uses AnteoBind in Luminex in-house vaccine quality control tests, supporting a vaccine portfolio that reaches approximately three out of every four children worldwide.

The sales pipeline expanded to 16 samples currently under evaluation, with eight in more advanced negotiation. New customers emerged in Japan, and distributor engagement is underway. Management highlighted re-engagement with large global life sciences companies, with the first phase of a joint CLIA product development programme incorporating AnteoBind NXT under final stages of negotiation.

Market development activities included attendance at BioAsia India (February 2026) and other sector conferences, alongside publication of a white paper comparing AnteoBind NXT performance versus Tosyl-activated magnetic particles in CLIA applications. The white paper supports performance claims and builds validation with diagnostic platform developers and large pharmaceutical companies.

Ongoing engagement continues with emerging diagnostic platforms including Vidcare, Fastsense, MOBIUS and others. While new technology approvals present additional challenges, they bring significant benefits in terms of integration into multi-test platforms and next-generation diagnostic systems.

LS product families and applications:

• Multiplex Activation kit: Used by SII for Luminex-based vaccine quality control.
• AnteoBind Biosensor: Supports next-generation immunodiagnostic test development, compatible with optical and electrical sensor formats.
• AnteoBind NXT: Delivers lower cost, higher performing (more sensitive and reliable) immunodiagnostic tests across lateral flow, CLIA particles and ELISA plate formats.

Life Sciences already has a marquee global customer in SII and is now broadening to additional big-pharma, big-diagnostics and regional customers. Every new evaluation and white paper builds validation, reducing the sales cycle and easing conversion into recurring reagent revenue.

Sales pipeline, strategy and what to watch in 2H FY26

AnteoTech’s expanding sales pipelines across ABT and LS represent the key leading indicator for future revenue growth. Management outlined clear targets for the second half of FY26, with a sharp focus on converting evaluations into contracts and JDAs.

Growing evaluation pipelines across both divisions

The volume and stage of opportunities increased materially during the half-year. As of February 2026, the ABT pipeline included 38 samples under evaluation, with 10 in sales or JDA negotiation. The LS pipeline included 35 samples in the funnel, with 16 under evaluation or work programme proposals and eight in more advanced negotiation.

Pipeline stages:

• Lead qualification: Initial contact and technical fit assessment.
• Sample provision: Dispatch of product samples for customer testing.
• Evaluation and feedback: Customer testing and performance validation.
• Negotiations: Commercial terms, pricing, and contract finalisation.

Key industry events attended or upcoming include:

• ABT: AABC Germany (June 2025), US Battery Show (October 2025), Interbattery South Korea (March 2026), International Battery Seminar USA (March 2026).
• LS: Lateral Flow San Diego (October 2025), AusBio (October 2025), BioAsia India (February 2026).

The growing number of evaluations across geographies is a leading indicator for potential future contracts and JDAs. Both divisions are now clearly in the commercialisation phase, with customer engagement and sample distribution replacing pure research and development activity.

Strategic priorities and milestones by 30 June 2026

The $3.5m (net) capital raise closed on 4 February 2026 provides runway to execute on management’s explicit 2H FY26 targets:

• New LS customer conversions and partnerships.
• New diagnostic product development in CLIA and ELISA formats.
• New ABT customers and JDA partnerships, including Ultranode 95 drone JDAs, SiMRAX early market test samples, and Anteo S sales.

Geographic focus areas include:

• India: SII contract expansion and new diagnostic customers.
• South Korea and Japan: Distributor-led growth in ABT separator and anode products, supported by Austrade and TIQ.
• USA and Europe: Commercial expansion across both ABT and LS divisions.

Key milestones to watch by 30 June 2026:

1. Additional SII orders and first new LS partner agreement secured.
2. Signing of at least one Ultranode 95 JDA in the drone or defence segment.
3. First commercial Anteo S separator order beyond sampling stage.
4. Progress announcement on SiMRAX JDA and Wyon integration outcomes.

(ASX: ADO) now combines a leaner cost base, a strengthened balance sheet, validated technology and expanding commercial pipelines in two structurally growing global markets. The transition from development spend to commercial execution is underway, with the second half of FY26 positioned to deliver material pipeline conversion if negotiations progress as management anticipates.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to stay ahead on Healthcare and Biotech developments the moment they hit the market.